DESIGN AND SYNTHESIS OF 4,6-DISUBSTITUTED QUINAZOLINE DERIVATIVES AS JANUS KINASE INHIBITORS

Janus kinases (JAKs) are recognized as important molecular targets in targeted therapy, and their inhibitors are widely used for the treatment of various autoimmune and inflammatory diseases. Although several JAK inhibitors have been approved by the U.S. Food and Drug Administration (FDA), the development of new compounds with improved selectivity and reduced toxicity remains highly relevant. In this study, a series of novel 4,6-disubstituted quinazoline derivatives were designed using a scaffold-hopping approach, and their targeted synthesis was successfully accomplished, providing a promising basis for the development of more effective JAK inhibitors.

Hali tarjima qilinmagan